Tempest Therapeutics Calls Special Meeting to Ease Supermajority Rules and Allow Written Consent
TPST is trading near its 52-week low of $0.93 (3.9% above the low).
Summary
Tempest Therapeutics filed a definitive proxy for a July 27 special meeting to vote on replacing supermajority voting requirements with majority standards and allowing stockholder action by written consent — governance changes that could streamline decision-making during a period of financial distress.
Key Events · Corporate Governance and Compliance · TPST
-
Special Meeting Called for July 27
Stockholders will vote on a proposal to amend the certificate of incorporation, replacing supermajority voting requirements with majority-of-outstanding standards and permitting stockholder action by written consent.
-
Governance Changes Proposed
The amendment would eliminate the 75% supermajority threshold for certain corporate actions and allow stockholders to act by written consent with majority approval, modernizing governance practices.
-
Financial Distress Context
Trading near its 52-week low, the company carries a going concern warning and recently received Nasdaq deficiency notices — making these governance changes potentially critical for future capital-raising or strategic moves.
-
Insider Ownership and Vote Dynamics
Directors and executive officers control 36.2% of outstanding shares, with CEO Matthew Angel holding 34.2%, likely ensuring strong support for the proposal despite the high 75% approval requirement.
Analysis · TPST · Life Sciences
Shareholders are being asked to approve governance changes that would lower the bar for future corporate actions. The proposal replaces 75% supermajority voting requirements with a simple majority-of-outstanding standard and permits stockholder action by written consent. This matters because Tempest Therapeutics is in a precarious position — trading near its 52-week low with a going concern warning and recent Nasdaq deficiency notices. Removing supermajority hurdles could make it easier to raise capital, approve dilutive transactions, or pursue strategic alternatives without a large shareholder blocking action. The special meeting is set for July 27, 2026, and the board unanimously recommends approval. With insiders controlling over 36% of the vote, passage is likely, but the high 75% approval threshold for this very proposal adds uncertainty.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 29.4% of the 1386 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TPST was trading at $0.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.4M. The 52-week trading range was $0.93 to $12.23. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.